2cureX AB (FRA:2QE) Scaled Net Operating Assets: -0.61 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2QE 2cureX AB FRA:2QE
37 GF Score
Price €0.16
! 3 Warning Signs
View Full Analysis

What is 2cureX AB Scaled Net Operating Assets?

2cureX AB FRA:2QE +0.38% 37 Scaled Net Operating Assets is -0.61 as of Jun. 2025. GuruFocus rates FRA:2QE with a GF Score™ of 37/100. The stock has 3 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

2cureX AB's operating assets for the quarter that ended in Jun. 2025 was €0.01 Mil. 2cureX AB's operating liabilities for the quarter that ended in Jun. 2025 was €0.41 Mil. 2cureX AB's Total Assets for the quarter that ended in Dec. 2024 was €0.67 Mil. Therefore, 2cureX AB's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2025 was -0.61.


2cureX AB Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for 2cureX AB's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2cureX AB Scaled Net Operating Assets Chart

2cureX AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.02 -0.02 0.11 -0.06

2cureX AB Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.18 -0.05 -0.06 -0.61

FRA:2QE vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, 2cureX AB's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


2cureX AB Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2cureX AB's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where 2cureX AB's Scaled Net Operating Assets falls into.


FRA:2QE
37GF Score
2cureX AB FRA:2QE
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

2cureX AB Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

2cureX AB's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(0.223-0.263)/0.632
=-0.06

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.67 - 0.447
=0.223

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.263 - 0 - 0
=0.263

2cureX AB's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2025 )
=(Operating Assets (Q: Jun. 2025 )-Operating Liabilities (Q: Jun. 2025 ))/Total Assets (Q: Dec. 2024 )
=(0.007-0.413)/0.67
=-0.61

where

Operating Assets(Q: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.47 - 0.463
=0.007

Operating Liabilities(Q: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.413 - 0 - 0
=0.413

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.61 mean?
2cureX AB (FRA:2QE) has a Scaled Net Operating Assets of -0.61 as of Jun. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on 2cureX AB and its competitors.
Is 2cureX AB's Scaled Net Operating Assets too high?
2cureX AB's current Scaled Net Operating Assets is -0.61. Overall, 2cureX AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does 2cureX AB's Scaled Net Operating Assets compare to VRTX and REGN?
2cureX AB's Scaled Net Operating Assets of -0.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on 2cureX AB and its competitors. 2cureX AB's current Scaled Net Operating Assets is -0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 2cureX AB stock overvalued right now?
2cureX AB (FRA:2QE) has a current Scaled Net Operating Assets of -0.61. The current Scaled Net Operating Assets is -0.61. 2cureX AB's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For 2cureX AB (FRA:2QE), the current Scaled Net Operating Assets is -0.61 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

2cureX AB Business Description

Other Exchanges 2CUREX:Sweden
Address Fruebjergvej 3, Copenhagen, DNK, DK-2100
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
37GF Score

Get the complete analysis for FRA:2QE

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price